SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging due to extreme volatility and high interest in its low-float structure, as traders pivot toward energy stocks amid renewed geopolitical tensions and supply disruptions in the Middle East. The community is actively debating the stock's squeeze potential while focusing on the broader, long-term thesis regarding Europe's urgent need for domestic natural gas reserves.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors weigh aggressive M&A expansion plans led by CEO Brad Jacobs against recent volatility, with community debate centered on whether to treat current price weakness as a long-term accumulation opportunity or a signal of overvaluation. The stock remains a focal point for discussion around its role in the building materials sector, with participants closely monitoring for the next acquisition announcement to provide renewed momentum.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is navigating significant volatility as the industry grapples with an unprecedented government shutdown that has triggered FAA-mandated flight capacity cuts and severe air traffic controller staffing shortages. Investors are intensely debating whether the airline's premium loyalty model provides a durable margin cushion or if the escalating operational disruptions and fuel price pressures from broader Middle East instability will weigh on upcoming performance.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies is attracting investor attention as its recent Variperm acquisition and deleveraging efforts signal a shift toward stronger free cash flow and potential share repurchases. The community is actively discussing the stock's valuation disconnect and its positioning as a key beneficiary of resilient international activity and rebounding natural gas drilling demand.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is experiencing significant volatility driven by the recent release of a negative short report and investor reactions to a large block share sale. Despite the pressure, the community remains heavily focused on the company's long-term potential as a domestic solar manufacturer, closely monitoring institutional buy-ins and expectations for upcoming earnings and offtake agreements.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as investors await critical updates following recent FDA interactions, with the community closely tracking potential news regarding the accelerated approval pathway for its lead ALS candidate, CNM-Au8. Discussions are heavily focused on the anticipation of new biomarker data and potential NDA submission updates, which shareholders view as primary catalysts for a significant valuation rerating.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors weigh potential federal regulatory shifts alongside a notable surge in beverage segment revenue, which some analysts believe could scale exponentially by the next decade. The community remains focused on the long-term impact of rescheduling and institutional accumulation, with many shareholders emphasizing patience as they navigate short-term price volatility and sector-wide regulatory developments.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing significant community attention as investors debate its potential for a major breakout, with many highlighting its resilience and year-to-date performance relative to other leading cryptocurrencies. The sentiment remains polarized, with bullish traders pointing toward upcoming network upgrades and whale accumulation, while skeptics express frustration over stagnant price action and compare the asset to other market alternatives.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is experiencing significant volatility as the market reacts to intense geopolitical instability in the Middle East, specifically regarding energy infrastructure and the potential closure of the Strait of Hormuz. Community discussion is sharply divided between bulls betting on a massive supply-driven price spike due to infrastructure damage, and bears highlighting the leveraged decay inherent in the product alongside bearish seasonal demand factors.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened community discussion surrounding the highly anticipated Goliath mainnet launch and potential enterprise-grade infrastructure developments. Investors are actively debating the token's long-term utility versus its history of volatility, with many monitoring for a sustained breakout while others caution against what they perceive as repetitive pump-and-dump market cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Buy the Dip in These Top-Ranked ETFs

Market volatility from Iran tensions has created dip-buying chances. Here are 5 ETFs across tech, semis, dividends, healthcare and financials.

<ul class="summary-bullets"><li>Net loss narrowed to $15.3 million from $18.1 million a year ago, while EBITDA loss improved to $3.2 million, compared with a loss of $9.1 million in the prior-year quarter.</li><li>The company credited its Butterfly Embedded platform strategy, including a partnership with Midjourney, for adding $6.8 million in Q4 revenue.</li><li>For fiscal 2026, Butterfly projects revenue between $117 million and $121 million.</li></ul>Butterfly Network, Inc. (BFLY) on Thursday reported strong fourth-quarter (Q4) and full-year 2025 results, highlighting expanding revenue growth and narrowing losses as it expands partnerships and advances its AI-driven imaging platform.The company posted Q4 revenue of $31.5 million, marking a 41% year over year (YoY) increase.&nbsp;<h2 class="st-heading-2">Quarterly Performance Surges</h2>U.S. sales climbed 55% YoY to $26.8 million, fueled in part by a new co-development collaboration with Midjourney and higher probe demand.&nbsp;Net loss narrowed to $15.3 million from $18.1 million a year ago, while adjusted loss per share (EPS) for the quarter was $0.02. Both revenue and EPS exceeded the analysts’ consensus estimates of $26.25 million and a loss of $0.07, respectively, according to Fiscal AI data.&nbsp;<a href="https://stocktwits.com/symbol/BFLY">Butterfly Network stock</a> traded over 23% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Expenses And Profitability Trends</h2>Operating costs increased 22% YoY to $37.9 million, reflecting stepped-up spending on sales and client experience initiatives. Excluding stock-based compensation and certain other items, operating expenses were $26.2 million.Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss improved to $3.2 million, compared with a loss of $9.1 million in the prior-year quarter. The company ended the year with $150.5 million in cash and equivalents and generated a positive net cash flow of $6.3 million in the quarter.The company credited its Butterfly Embedded platform strategy, including a partnership with Midjourney, for adding $6.8 million in Q4 revenue. The broader agreement, disclosed in November, outlines potential payments totaling up to $74 million over five years.For fiscal 2026, Butterfly projects revenue of $117 million to $121 million, representing growth of roughly 20% to 24%. BFLY stock has declined by over 21% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/prct-stock-tumbles-pre-market-bof-a-questions-earnings-visibility-cuts-target-to-20/cZTGJmTRIbn">PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lower Saxony, Heiligenrode: Doctor Umes Arunagirinathan at work in the Heiligenrode GP practice.

Why Did BFLY Stock Surge More Than 23% Pre-Market Today?

The company posted Q4 revenue of $31.5 million, marking a 41% increase year-on-year (YoY), while the adjusted loss per share (EPS) for the quarter was $0.02.

Equity

The company posted Q4 revenue of $31.5 million, marking a 41% increase year-on-year (YoY), while the adjusted loss per share (EPS) for the quarter was $0.02.


Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

<ul class="summary-bullets"><li>The results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial.&nbsp;</li><li>Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles.</li><li>Patient-reported outcomes also indicated reduced cravings for sweet foods.</li></ul>Fractyl Health, Inc. (GUTS) announced on Thursday positive six-month findings from its ongoing REMAIN-1 Midpoint Cohort, a study evaluating Revita for weight maintenance after patients discontinue GLP-1 therapy.The six-month data, covering 40 participants, suggest that Revita helps limit weight regain following GLP-1 discontinuation, with treated patients regaining 4.5% of weight versus 7.5% in the sham group.<h2 class="st-heading-2">Midpoint Study Shows Promising Results</h2>An exploratory analysis of those who lost above-median weight during the GLP-1 run-in showed a 70% relative reduction in post-GLP-1 weight regain for Revita-treated participants compared with sham.&nbsp;These results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial. Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles, including higher HDL cholesterol and a lower triglyceride-to-HDL ratio.&nbsp;Patient-reported outcomes also indicated reduced cravings for sweet foods, suggesting that the device may influence appetite and metabolism through gut-mediated mechanisms.However,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">Fractyl Health's stock</a> plummeted 63% in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Despite the fall in the stock’s price, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_29_085922_png_07f795b807.webp" alt="GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits" width="930" height="110"><figcaption>GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the product that reduces sweet cravings could be extremely profitable, highlighting huge market potential.<stembedurl>https://stocktwits.com/BioRich/message/643264512</stembedurl>Another user said they trusted the management and would hold the stock.&nbsp;<stembedurl>https://stocktwits.com/CocoPeechu/message/643264755</stembedurl>Revita, the main product from Fractyl Health, is meant to reshape the lining of the small intestine through a single, minimally invasive procedure. The FDA has granted Revita Breakthrough Device designation to help people maintain weight after stopping GLP-1 treatments.The company also outlined upcoming catalysts, including one‑year cohort readouts and pivotal REMAIN‑1 data later this year, which could support a future U.S. marketing application.GUTS stock has declined by over 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-now-stock-is-falling/cmyifBjR4KZ">NOW Stock Falls 9% After Q4 Beat: Why Have Analysts Cut Price Targets?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? 

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

<ul class="summary-bullets"><li>The patents issued cover critical aspects of Glucotrack’s implantable CBGM technology.</li><li>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood.</li><li>The long-term, fully implantable design offers more convenient option for diabetes management.</li></ul>Glucotrack, Inc. (GCTK) announced on Thursday that it has secured three new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.&nbsp;The patents are expected to boost the company’s intellectual property portfolio as it moves its long-term implantable monitoring system closer to commercialization.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> traded over 12% higher in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">New Patents Strengthen IP</h2>The US Patent and Trademark Office issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258, covering critical aspects of Glucotrack’s implantable CBGM technology.The patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all integral to the company’s implantable system.On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Clinical And Practical Significance</h2>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood. This approach is expected to provide near real-time readings, eliminating the lag commonly seen with subcutaneous sensors.&nbsp;<blockquote>“Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization.”-Paul V. Goode, President and CEO, Glucotrack</blockquote>The long-term, fully implantable design also aims to reduce patient burden and improve adherence, offering a potentially more convenient option for diabetes management.Glucotrack’s CBGM is a fully implantable device that tracks blood sugar continuously for up to three years. It does not require any wearable parts on the body and needs very little calibration.&nbsp;GCTK stock has declined by over 97% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-guts-stock-fell-revita-post-glp1-data/cmyig4sR4KA">Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A young girl suffering from diabetes type 1, squeezes air bubbles out of her catheter.

Why Did Glucotrack Stock Surge 12% Pre-Market Today?

The company has received patents for its continuous blood glucose monitoring system.

<ul class="summary-bullets"><li>The company went public in 2019 at a post-money valuation of $480 million, according to the report.&nbsp;</li><li>InMode has been facing declining sales and profits since 2023.</li><li>On January 9, the&nbsp;company said it anticipated its fourth-quarter sales to fall within a tight range of $103.6 million to $103.8 million.</li></ul>InMode stock became the talk of the town on Monday after a report stated that the company is set to be acquired by&nbsp;an investment fund in a deal that values the firm at roughly $1.1 billion, marking a 25% premium over its current Nasdaq trading value of $882 million.&nbsp;According to a Calcalist&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.calcalist.co.il/market/article/hjurxpfizl">report</a>, the transaction will result in InMode being taken private and removed from public trading.<a href="https://stocktwits.com/symbol/INMD">InMode stock</a> traded over 13% higher on Monday morning.&nbsp;<h2 class="st-heading-2">Background and Valuation</h2>Founded in 2008 by Moshe Mizrahi, the firm's CEO, and Michael Kreindel, the firm's Chief Technology Officer, the company originally developed advanced minimally invasive aesthetic treatments using radio frequency (RF) technology. It went public in 2019 at a post-money valuation of $480 million and reached a peak market value of $7 billion in 2021.Following the report, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘high’ message volume levels on Stocktwits.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_26_092338_png_08dfdb451a.webp" alt="INMD’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Jan. 26, 2026 | Source: Stocktwits" width="928" height="106"><figcaption>INMD’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Jan. 26, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Financial Challenges</h2>According to the report, InMode has been facing declining sales and profits since 2023, partly due to rising interest rates in the U.S. and an economic slowdown that affected financing for doctors purchasing its devices.&nbsp;The U.S. Food and Drug Administration’s (FDA) warning last October about health problems linked to some radiofrequency (RF) microneedling devices in general affected the stock.&nbsp;On January 9, the&nbsp;company said it anticipated its fourth-quarter (Q4) sales to fall within a tight range of $103.6 million to $103.8 million, below the analysts' consensus estimate of $104.64 million, according to FiscalAI data. Furthermore, the company’s 2025 revenue outlook of $370.2 million to $370.4 million is also below the analysts' consensus estimate of $371 million.INMD stock has declined by over 8% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crwv-stock-soars-nvidia-2-billion-investment-ai-infrastructure/cmy7qzrR4h2">CRWV Stock Soars 10% Pre-Market As Nvidia Invests $2B To Expand AI Factory Network</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 A worker produces medical instrument at Shandong Yixing Medical Instrument Co., Ltd.

INMD Stock Jumped Nearly 13% Today – What’s Powering The Rally?

According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund. 

Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan

Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.

<ul class="summary-bullets"><li>The company sees 2025 revenue of $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.</li><li>BRIUMVI’s U.S. net product revenue expected to reach around $182 million in Q4 and $594 million in 2025.&nbsp;</li><li>TG Therapeutics stock rallies 9% higher in Wednesday’s premarket.&nbsp;</li></ul>TG Therapeutics, Inc. (TGTX) drew increased attention on Wednesday, with the stock seeing a 195% increase in retail chatter on Stocktwits over the last 24 hours following the company’s ambitious revenue outlook.&nbsp;On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/TGTX">TG Therapeutics stock</a> traded over 9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_14_083034_png_390ef2e760.webp" alt="TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits" width="933" height="108"><figcaption>TGTX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 14, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic about BRIUMVI achieving blockbuster status.<stembedurl>https://stocktwits.com/knowthyself/message/641747123</stembedurl>Another bullish user said the company’s ramp-up from Q3 to Q4 was impressive.&nbsp;<stembedurl>https://stocktwits.com/Uncle_Baby_Billy/message/641752748</stembedurl><h2 class="st-heading-2">Outlook Highlights&nbsp;</h2>TG Therapeutics expects BRIUMVI’s U.S. net product revenue to reach around $182 million in Q4 and $594 million for the full year of 2025. Global revenue for the year is estimated at $616 million compared to the analysts’ consensus estimate of $606.03 million, according to Fiscal AI data.&nbsp;Looking ahead, the company anticipates total global revenue between $875 million and $900 million for 2026, with U.S. BRIUMVI sales projected at $825 million to $850 million.BRIUMVI is a glycoengineered monoclonal antibody that targets CD20-expressing B-cells, a proven approach for treating autoimmune diseases like relapsing multiple sclerosis (RMS). By removing specific sugar molecules, BRIUMVI enhances B-cell depletion at lower doses.<h2 class="st-heading-2">Upcoming Clinical Milestones</h2>The company also teased three major milestones for 2026.&nbsp;TG Therapeutics plans to release pivotal topline data for the ENHANCE trial, which evaluates Day 1 and Day 15 intravenous doses of BRIUMVI, by mid-2026. Preliminary Phase 1 data for azer-cel in Progressive multiple sclerosis (MS) will be shared in the latter half of the year.&nbsp;Pivotal topline results for subcutaneous BRIUMVI are expected by year-end 2026 or early 2027.&nbsp;TGTX stock has declined by over 6% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Biology lab technician removes a freeze-dried sample from a container in a laboratory.

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

<ul class="summary-bullets"><li>Tempus’ 2025 Total Contract Value (TCV) exceeded $1.1 billion.</li><li>The 2025 agreement roster includes global pharma companies such as AstraZeneca, GlaxoSmithKline, and Pfizer.</li><li>Revenue from data and software-based offerings is expected to be approximately $316 million for 2025.</li></ul>Tempus AI, Inc. (TEM) stock gained over 11% in Monday’s premarket after the company reported that its Total Contract Value (TCV) surpassed $1.1 billion by the end of December 2025.Tempus uses artificial intelligence to work with large and diverse sets of medical data and provides tools that help doctors make more personalized treatment decisions.<h2 class="st-heading-2">Record Contract Growth</h2>Tempus secured data and analytics agreements with more than 70 organizations in the last year, showing the broad adoption of its multimodal data platform.&nbsp;The 2025 agreement roster spans global pharmas such as AstraZeneca, GlaxoSmithKline, Pfizer, Novartis, and Merck alongside biotech partners like Incyte and Whitehawk Therapeutics.&nbsp;<blockquote>“Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond.”-Jim Rogers, CFO, Tempus</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/TEM">Tempus AI stock</a> moved to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Retention And Revenue Strength</h2>Tempus also reported strong client retention, with net revenue retention around 126% as existing users increased their commitments in 2025.&nbsp;The company also released its outlook for both the fourth quarter (Q4) and the full year of 2025. For the year ending Dec. 31, 2025, Tempus expects total revenue to reach roughly $1.27 billion, a whopping 83% year-over-year increase. The company sees diagnostic testing as the primary growth engine, generating about $955 million in annual revenue.&nbsp;Revenue from data and software-based offerings is expected to be approximately $316 million for the year. For Q4, Tempus expects revenue to climb to nearly $367 million.&nbsp;TEM stock has gained over 104% in the last 12 months.&nbsp;Also See:<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slips-as-amazon-turns-up-heat-on-weight-loss-drugs/cmU9u36R43M"> Why Is HIMS Stock Slipping Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tempus AI logo is seen displayed on a smartphone screen.

Why Is Tempus AI Stock Surging 11% Premarket Today? 

Tempus secured data and analytics agreements with more than 70 organizations in 2025, showing the broad adoption of its multimodal data platform. 

Current Price	$54.44
Prev Close	$54.87
Open	$54.82
Dividend Yield	N/A
50-Day Moving Average	$59.05
Beta	N/A
Avg. Volume	2.31M
PE Ratio	N/A

52-Week High	$64.71
52-Week Low	$52.90
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IHI
iShares US Medical Devices ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHI News

IHIiShares US Medical Devices ETF